Sarepta Therapeutics, Inc. (SRPT) Strategic Restructure and ELEVIDYS Label Update Call Transcript

Sarepta Therapeutics announced a significant strategic restructuring aimed at ensuring long-term financial viability and pipeline focus, including a 36% workforce reduction and projected annual cost savings of $400 million from 2026. The company will reprioritize its pipeline to high-impact siRNA programs like FSHD, DM1, and SCA2, while seeking partnerships for deprioritized assets. Regarding its Duchenne franchise, Sarepta agreed to an FDA-requested black box warning for ELEVIDYS in ambulatory patients, resolving key label issues, and is proposing a sirolimus immunosuppression protocol for non-ambulatory patients via a new clinical study after voluntarily pausing shipments for this group. Sarepta emphasized that even under a conservative 'stress test' scenario of $1.4 billion in annual Duchenne revenue (including a $500 million floor for ambulatory ELEVIDYS), it can meet its 2027 debt obligations and maintain financial flexibility.

Analysis

Sarepta Therapeutics is executing a significant strategic restructuring in response to recent adverse events, primarily the two fatal acute liver failure (ALF) cases associated with its gene therapy, ELEVIDYS, in non-ambulatory patients. The company is taking decisive action to de-risk its financial profile by reducing its workforce by 36% (approx. 500 employees) and narrowing its pipeline focus, targeting approximately $400 million in annualized cost savings starting in 2026. For its key asset ELEVIDYS, the company has stabilized the ambulatory patient market by agreeing to an FDA-requested black box warning, but has voluntarily paused dosing in the non-ambulatory population, creating significant uncertainty for that segment's outlook. Management is proactively addressing this by proposing a new clinical study to evaluate a sirolimus-based immunosuppression regimen to mitigate liver toxicity risk, a critical step that requires FDA alignment.

Financially, the company has shifted from providing formal guidance to outlining a conservative 'stress test' revenue floor of over $1.4 billion annually, composed of a stable ~$900 million from its PMO franchise and a minimum of $500 million from the ELEVIDYS ambulatory population. This baseline is explicitly intended to reassure investors of its ability to maintain profitability, service its $600 million revolving credit facility, and address its 2027 convertible debt obligations. The strategic pivot away from most of its limb-girdle programs to its siRNA platform (FSHD, DM1, SCA2) makes the upcoming data readouts in the second half of 2025 pivotal catalysts. These results will be the first major test of this new, more focused R&D strategy and are crucial for rebuilding long-term growth narratives beyond the Duchenne franchise.

Key Decisions for Investors

• Investors should re-baseline ELEVIDYS revenue models around the more certain ambulatory opportunity, using the company's stated $500 million annual floor as a conservative foundation, while treating the non-ambulatory segment as a high-risk call option contingent on FDA feedback for the proposed sirolimus safety protocol.
• The upcoming preliminary data for the FSHD and DM1 siRNA programs in H2 2025 are now pivotal catalysts; positive safety and target knockdown results are essential to validate the company's strategic pivot and provide a tangible path to future growth beyond the Duchenne franchise.
• Monitor the company's operating expenses and cash flow quarterly to track progress towards its projected $400 million in annual cost savings, as achieving this target is critical to managing its 2027 convertible debt without resorting to potentially dilutive financing.
• The stability of the ~$900 million PMO franchise provides a crucial financial backstop, but any signs of accelerated decline or competitive pressure on this base should be considered a material risk to the company's entire financial plan.